SWOG Selects Sequenta’s LymphoSIGHT™ Platform for Use in 180-Patient Mantle Cell Lymphoma Clinical Trial
09:00 EDT 6 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Sequenta, Inc. announced today that SWOG has selected Sequenta’s
LymphoSIGHTâ„¢ platform for the measurement of Minimal Residual Disease
(MRD) in a clinical trial.
The SWOG S1106 Mantle Cell Lymphoma (MCL) trial, a co...
Other Sources for this Article
For Sequenta, Inc.
Jon Schmid
619-814-2370 ext. 12
jschmid@cookandschmid.com
More From BioPortfolio on "SWOG Selects Sequenta’s LymphoSIGHT™ Platform for Use in 180-Patient Mantle Cell Lymphoma Clinical Trial"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
